197 related articles for article (PubMed ID: 30611741)
1. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
2. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
3. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibition of MYC-amplified medulloblastoma.
Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
[TBL] [Abstract][Full Text] [Related]
6. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
7. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
10. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
11. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
12. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
13. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Vázquez R; Licandro SA; Astorgues-Xerri L; Lettera E; Panini N; Romano M; Erba E; Ubezio P; Bello E; Libener R; Orecchia S; Grosso F; Riveiro ME; Cvitkovic E; Bekradda M; D'Incalci M; Frapolli R
Int J Cancer; 2017 Jan; 140(1):197-207. PubMed ID: 27594045
[TBL] [Abstract][Full Text] [Related]
14. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.
Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S
Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983
[TBL] [Abstract][Full Text] [Related]
15. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract][Full Text] [Related]
16. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
17. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
18. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
19. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
[TBL] [Abstract][Full Text] [Related]
20. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
